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ABSTRACT
Objectives: Anticoagulation is used in patients with atrial
ﬁbrillation to reduce the risk of ischemic stroke. The therapy
requires regular monitoring and, frequently, dose adjustment.
This study aimed to determine the time and traveling costs
that patients incur to themselves and society in attending
anticoagulation clinics.
Methods: A subset of patients from 105 primary and sec-
ondary care clinics allocated to the warfarin arm of SPORTIF
III (patients from Australia, France, Portugal, Spain, Sweden,
and the UK) completed a questionnaire. Patients indicated
the type of transport used for clinic visits, and estimated
traveling expenses. Patients were also asked to estimate total
traveling and clinic attendance time, and to conﬁrm whether
they were currently employed and whether they had to give
up time from work to attend the clinic. Time cost of com-
panions was also taken into consideration. Cost per visit was
calculated (€, 2003 prices).
Results: Questionnaires for a total of 381 patients were ana-
lyzed, with the majority of patients from Sweden (n = 130)
and the UK (n = 101). Mean cost to patients varied widely
between countries, ranging from €6.9 (France) to €20.5
(Portugal) per visit. For most countries, time costs (value of
lost working and leisure time) were the main driver of costs.
Mean time cost to society ranged from €5.6 (France) to €31.7
(Portugal) per visit.
Conclusions: Patients incur considerable costs when visiting
anticoagulation clinics, and these costs vary by country. The
results suggest the importance of taking a broad economic
perspective when considering the cost-effectiveness of
warfarin.
Keywords: anticoagulants, atrial ﬁbrillation, cost analysis,
warfarin.
Introduction
Anticoagulation therapy, particularly warfarin, has
been recommended for a number of clinical indica-
tions, most notably atrial ﬁbrillation (AF) [1–3].
Nevertheless, very serious and often life-threatening
adverse events are associated with warfarin therapy,
and so regular coagulation monitoring is required.
This involves a blood test to measure the international
normalized ratio (INR), on the basis of which adjust-
ments to therapy can be made to ensure safety and
efﬁcacy––the aim is to minimize the risk of thrombotic
and/or hemorrhagic events. Typically, the monitoring
involves patients attending a clinic, with the number of
clinic visits per annum dependent on the level of INR
control achieved [4]. In the UK, the frequency is com-
monly in the range of 8 to 12 visits per year.
Patients incur costs to themselves and society when
travel to a clinic is required. Costs to the patients
include traveling costs, other out-of-pocket expenses,
value of lost leisure time, and net wage deduction
associated with employed patients’ clinic visits during
working time. Additional costs to society include the
difference between patients’ net wage and the full value
of the production loss, and the value of companions’
time. Many economic evaluations tend to be carried
out from a health sector perspective (i.e., those paying
for the health care), and thus ignore the additional
time and traveling costs associated with receiving
health-care services, which in some cases are consider-
able [5–8].
Parry et al. [8] showed patients incurred costs
when attending primary or secondary anticoagulation
clinics. Costs were higher for secondary care clinics
(€23.6) compared to primary care (€11.0) (2003
prices), and these differences were driven by the time
required to travel to and from the clinic, the mode of
transport used, and the time spent within the clinic
itself.
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The objective of this work was to determine the
time and traveling costs that patients incur to them-
selves and society in attending anticoagulation clinics.
The study builds on the work by Parry et al. [8] and
considers the magnitude of patient costs when attend-
ing routine anticoagulation clinics, and explores the
main drivers of these costs. The article also considers
the total time cost to society incurred by patients and
companions who went with the patient for the clinic
visit. In addition, because the data reported in this
article are drawn from several countries, the analysis
also provides a multinational comparison of time and
traveling costs associated with attending anticoagula-
tion clinics.
Method
SPORTIF III (Stroke Prevention using an ORal Throm-
bin Inhibitor in atrial Fibrillation) was a large random-
ized controlled trial of stroke prevention with the
oral-direct thrombin inhibitor ximelagatran compared
to warfarin in patients with AF [9]. Signed informed
consent was required from every participant according
to a protocol approved by local ethics committees and
in accordance with the Declaration of Helsinki.
From this trial, a subset of patients allocated to
the warfarin arm of the trial (patients from Australia,
France, Portugal, Spain, Sweden, and the UK) were
invited to take part in the time and traveling cost
substudy and complete a questionnaire asking about
time and out-of-pocket expenses associated with their
routine care. Each patient was asked to give this
information for two separate coagulation monitoring
visits. To ensure that the data related to routine care
and not study-speciﬁc tasks, patients were instructed
to complete the questionnaires in connection to a
visit where only an INR measurement was under-
taken. The substudy was carried out between Septem-
ber 2001 and June 2002. The questionnaire used
in the substudy is available from the authors on
request.
The approach to coagulation monitoring in the trial
(e.g., whether in primary or secondary care) was in line
with the typical approach to monitoring in each
country. Across the substudy, the majority of centers
operated a hospital-based approach. In France, most
of the study centers used home monitoring, organized
speciﬁcally by the sponsor for the purpose of the study.
Because the focus for this article is the costs associated
with routine anticoagulation clinic visits, home-
monitoring patients were excluded from the analysis.
Data were collected on traveling costs, fees paid by
patients for the visit to the clinic, and time costs. In
addition, information was also collected on the time
costs incurred by companions who accompanied the
patient on the clinic visit.
Traveling Costs
Patients were asked to state the type of transport used
to get to and from the clinic. In addition, they were
asked to estimate the distance from their home to the
clinic. The purpose of this question was for the esti-
mation of the motoring costs for those who traveled
by private car. For each country, an estimate of the
national motoring cost per kilometer was applied
(Table 1). Other traveling expenses that were quanti-
ﬁed included parking fees, public transport and/or taxi
fares, and mobility services costs. The sum of these
component costs gave the total traveling cost per visit.
Fee Paid by Patients
Patients were asked whether they had to pay a fee for
the visit to the clinic and, if so, how much they had to
pay.
Time Costs
Patients were asked to estimate the total time involved
in their visit, including total traveling and clinic
attendance time. In addition, data were collected on
employment status and whether the patient had to give
up time from work to attend the clinic. Working time
sacriﬁced for the clinic attendance was valued at the
national average net wage rate per hour. Local esti-
mates of average gross wages were converted into net
wages using average personal income tax and social
security contribution rates (Table 1). An additional
cost to society for working time lost (i.e., production
time lost) was also accounted for. Where individuals
reported work time given up, the additional cost was
estimated as the difference between the average total
labor costs and the net wage cost to the patient.
In line with assumptions used in previous work on
time costs, where time was not given up from work the
time was classiﬁed as “leisure time” and valued at
35% of the local average gross wage (Table 1) [10].
The same value for leisure time was also used for
Table 1 Unit costs by country (€, 2003 prices)
Australia France Portugal Spain Sweden UK
Motoring costs per km 0.33 0.40 0.34 0.17 0.18 0.47
Labor cost per hour 16.89 26.96 8.79 15.09 22.43 22.80
Gross wage per hour 14.00 14.62 7.01 11.39 16.05 16.59
Net wage per hour 10.77 11.65 5.86 9.24 10.97 12.73
Leisure time per hour 4.90 5.12 2.45 3.99 5.62 5.81
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patients not in paid employment––for example, those
who were retired. The time cost of companions was
also taken into consideration. Patients were asked
whether anyone accompanied them to the clinic,
whether the companion was currently employed, and,
if so, whether that person had to give up time from
work. Working and nonworking time was valued in
the same way as described earlier for the patient.
Analysis
The analysis was conducted using the software SAS
version 8.02 (SAS Institute Inc., Cary, NC, USA). All
costs were converted to Euros and adjusted to a
common price base of 2003 prices. Unit costs used in
the calculations are available from the authors on
request. A total patient cost per visit was calculated,
using the data from each questionnaire, by adding
together the traveling costs, fee paid by patients, and
time costs. A total societal time cost per visit was also
calculated by adding together the costs for patients’
and companions’ working and leisure time.
In the base-case analysis, where a patient had com-
pleted both questionnaires (for visits 1 and 2), a mean
cost per visit across the two visits was used. When data
were missing in one questionnaire but not the other,
the supplied data applied to both (“last value carried
forward”). If question-speciﬁc data were missing from
both questionnaires, the patient was excluded from the
analysis.
Proportions and means were calculated, and the
data for each country were analyzed separately.
Because of the non-normal nature of the cost data, the
nonparametric approach of bootstrapping was used to
calculate the 95% conﬁdence intervals (CIs) around
the mean cost estimates [11].
Sensitivity Analyses
Two sets of sensitivity analyses were performed: the
ﬁrst dealing with missing data concerns, and the
second exploring the leisure time valuation assump-
tion. The effect of missing data on the overall results
was investigated as follows:
• ﬁrst, all missing data were assumed to be zero;
• second, a complete case analysis was undertaken,
where only patients with two fully completed
questionnaires were included.
In two additional sensitivity analyses, leisure time
per hour was valued at 15% and 50% of the local
average gross wage.
Results
A total of 511 SPORTIF III patients were randomized
to warfarin in the six countries that participated in the
time and traveling cost substudy. A total of 460
patients (90%) returned at least one questionnaire,
and 381 (83%) provided data that could be used in
the base-case analysis. The last-value-carried-forward
technique was used in a total of 102 patients (27%). A
total of 25 patients (5%) were excluded due to lack
of question-speciﬁc data in both questionnaires. In
France, a total of 54 home-monitoring patients (59%)
were excluded from the analysis. The distribution of
patients by country is available from the authors on
request.
Individual patient-level information on the type of
clinic attended (primary or secondary care) by study
patients was not available although, as indicated
above, the SPORTIF III trial required monitoring to
be in line with local clinical practice. Patients from
Australia, Portugal, Spain, Sweden, and the UK were
known to attend hospitals or specialist clinics, and
patients from France were a mix of either primary or
secondary care service users.
Age and sex distributions were similar across coun-
tries. In patients who returned at least one question-
naire, mean age ranged from 70 (Australia) to 74 years
(France and the UK). The proportion of women ranged
from 26% (France, Spain and the UK) to 38%
(Portugal). In the overall SPORTIF III trial, the war-
farin cohort mean age was 70 years and 30% were
women [9]. A summary of some of the key data from
the questionnaires (for visits 1 and 2) is given in
Figure 1 and Table 2. Private car was the most popular
form of transport in all countries, except for Spain,
where more patients went by public transport. Portu-
guese patients traveled the furthest and spent the
longest time traveling to and attending the clinic. In
Spain and Portugal, approximately 60% of atten-
dances involved a companion. The highest proportion
of employed patients was seen in Australia and the
lowest proportion in the UK.
Table 3 shows the breakdown of patient cost com-
ponents by country. The lowest patient cost per visit
was seen in France (primary care) and the highest in
Portugal. The high patient cost for Portugal appears
to be driven principally by the high time costs (result-
ing from longer time periods involved in travel and
clinic attendance). Costs for Australia, France (sec-
ondary care), Spain, Sweden, and the UK were at a
similar level, although an important difference is that
in Sweden, approximately 35% of patients were
required to pay a fee to attend a clinic––this was not
the case in the other countries, where relatively few
patients incurred a fee, with a range from 0%
(France) to 13% (Portugal). For all countries except
France, the main cost driver was the cost of the
patient’s time. Table 3 also shows the total societal
time cost per visit. The lowest cost was seen in France
(primary care) and the highest in Portugal and Spain.
The high costs in Portugal and Spain appears to be
driven principally by the larger companion attendance
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rates, in addition to longer time periods involved in
travel and clinic attendance.
The sensitivity analysis results are reported in
Table 4. In the analysis, where missing values were set
to zero, the costs were reduced for every country as
expected, with the greatest impact for Portugal.
Further sensitivity analysis estimated costs only for
those patients where complete data were available for
both questionnaires. For Spain and Sweden, only small
relative differences were seen between these results and
those for the base case. Note that the French and
Portuguese costs were based on very few observations.
Finally, varying the leisure time valuation had a great
impact on the results.
Discussion
This study demonstrates that patients incur consider-
able time and traveling costs when visiting anticoagu-
lation clinics. The costs are still appreciable even
though most of the patients in this study stated that
they were not employed.
Figure 1 Type of transport that the patients
used to get to and from the clinic.
Table 2 Descriptive data from questionnaires (for both visits 1 and 2)
Australia
(n = 49)
France
(n = 91)
Portugal
(n = 21)
Spain
(n = 53)
Sweden
(n = 135)
UK
(n = 111)
Mean distance traveled (km) 6 8 10 6 9 8
Time for travel and clinic (hours) 1.0 0.7 3.5 2.7 1.3 1.3
Currently employed (%)* 21 5 13 11 11 4
Accompanied (%)* 13 9 68 60 10 19
*Patients with missing data were excluded from calculations of percentages.
Table 3 Mean patient cost per visit and mean societal time cost per visit, base-case analysis (€, 2003 prices)*†
Australia
(n = 46)
France
Portugal
(n = 16)
Spain
(n = 53)
Sweden
(n = 130)
UK
(n = 101)
Primary care
(n = 19)
Secondary care
(n = 16)
Traveling costs 4.2 4.1 7.1 7.7 3.0 3.5 4.4
Fee paid by patients 0.4 0.0 0.0 0.4 0.1 2.8 0.0
Time costs to patients
Working time 1.5 0.0 0.0 4.5 2.2 0.9 0.7
Leisure time 3.9 2.8 4.6 7.9 10.0 7.1 7.1
Total patient cost 10.0
(7.8–12.5)
6.9
(4.3–9.8)
11.7
(5.6–21.9)
20.5
(14.3–28.0)
15.3
(13.0–17.5)
14.3
(12.9–15.8)
12.2
(10.4–14.3)
Additional time costs to society‡
Working time (patients) 0.8 0.0 0.0 2.2 1.3 0.9 0.6
Working time (companions) 0.0 0.0 0.0 11.0 4.3 0.0 3.5
Leisure time (companions) 4.5 2.8 4.6 6.1 9.7 7.4 6.9
Total time cost to society‡ 10.7
(8.6–13.2)
5.6
(4.3–6.8)
9.2
(6.8–11.8)
31.7
(22.7–41.2)
27.5
(23.1–32.4)
16.3
(14.6–18.0)
18.8
(15.2–23.9)
*Bootstrap 95% CIs are given within parentheses.
†Results for Australia, Portugal, Spain, Sweden, and the UK refer to secondary care.
‡Time costs to patient and additional time costs to society.
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Time and traveling costs varied between the coun-
tries, and this variation may be related to several
factors. First, there may be health service organization
factors, in terms of the running of the anticoagulation
clinic, which determine the amount of patient time
involved in the clinic visit. Socioeconomic and cultural
factors may come into play, for example, access to a
car, use of public transport, and the likelihood of the
patient being accompanied. Finally, economic issues
are involved, such as the rate of employment in a
country, and wage and labor cost levels.
This study of time and traveling costs is one of the
largest undertaken, and certainly the largest among
anticoagulation patients. In addition, it is the ﬁrst
international comparison of such costs. Most studies
of this nature rely on data collection from a single visit;
therefore, this study has the advantage of collecting
data on two visits, which allowed the assessment of
within-subject cost variability.
Previous work on time and traveling costs for UK
patients attending warfarin clinics calculated a mean
cost per visit to a secondary care clinic of €23.6 (2003
prices) [8]. The mean costs for UK patients in this
study are lower (€15.5). One possible explanation for
this is the lower mean age of patients (67.5 years) in
the Parry et al. study [8]; therefore, more patients may
have been employed, resulting in higher time costs.
Further studies conducted in the UK have investigated
patient costs incurred when attending screening for
colorectal cancer or abdominal aortic aneurysm (AAA)
[5–7]. Slightly lower costs were reported with AAA
screening at a hospital clinic (€12.4, 2003 prices), and
higher mean costs were reported for colorectal cancer
screening at €27.3 (2003 prices). Nevertheless, for the
latter study, patients were aged between 50 and
74 years; therefore, a higher proportion of subjects
may have been employed. When comparing studies, it
is important to be aware that there is no consensus of
opinion on the methods for valuing patient time and
there are particular difﬁculties with valuing leisure
time.
Time and traveling costs may have some impact if
there is a comparison of costs of alternative models of
anticoagulation care. In the Parry et al. article [8], the
costs of primary and secondary care anticoagulation
were about the same if patient costs were added, com-
pared to much lower secondary care costs if from a
health-care perspective only. Patient-level data on the
approach to coagulation monitoring was not recorded
in this study, but patients in all countries except France
were known to attend secondary care clinics. Thus,
analysis of variation in time and costs between primary
and secondary care providers was possible only for
patients from France, where costs were higher for sec-
ondary care patients. This is in line with the previous
work by Parry et al. [8], which demonstrated the
higher mean patient cost per visit to a hospital clinic
compared to a primary care clinic.
Because time and traveling costs add to the cost of
anticoagulation, these should ideally be included when
undertaking cost-effectiveness analysis of different
anticoagulation options. The impact of these costs on
the cost-effectiveness of anticoagulation will depend
on whether or not the compared anticoagulation
options do require coagulation monitoring, the model
of anticoagulation care, the frequency of coagulation
monitoring, and the magnitude of the time and trav-
eling costs per visit. The results may also have wider
relevance for any treatment requiring regular monitor-
ing and secondary care clinic visits, where the patient
Table 4 Mean patient cost per visit and mean societal time cost per visit, sensitivity analysis* (€, 2003 prices)
Missing values
set to zero
Complete data available
for both questionnaires
Leisure time per hour valued at:
15% of the gross wage
per hour
50% of the gross wage
per hour
Total patient cost
Australia 8.4 (6.3–10.6) [49] 9.8 (7.3–13.1) [28] 7.7 (5.8–10.0) [46] 11.6 (9.3–14.5) [46]
France (primary care) 6.1 (3.5–9.2) [19] 9.4 (5.5–13.7) [11] 5.3 (2.9–8.1) [19] 8.0 (5.3–11.2) [19]
France (secondary care) 8.9 (3.7–18.0) [18] 5.7 (3.8–7.6) [7] 9.1 (3.1–18.5) [16] 13.7 (7.2–24.4) [16]
Portugal 11.9 (8.2–16.1) [19] 18.2 (9.6–27.3) [3] 15.9 (9.5–23.9) [16] 23.9 (18.1–30.9) [16]
Spain 14.8 (12.4–17.1) [53] 15.5 (13.3–18.0) [48] 9.5 (7.4–11.9) [53] 19.6 (17.1–22.1) [53]
Sweden 12.4 (10.8–14.1) [135] 14.5 (12.6–16.4) [96] 10.3 (8.9–11.7) [130] 17.3 (15.7–19.0) [130]
UK 9.1 (7.7–10.4) [110] 11.0 (9.5–12.7) [56] 8.2 (6.4–10.2) [101] 15.3 (13.4–17.5) [101]
Total time cost to society†
Australia 9.0 (6.9–11.1) [49] 9.4 (7.8–11.0) [28] 5.9 (4.1–8.0) [46] 14.3 (11.7–17.2) [46]
France (primary care) 4.4 (3.3–5.6) [19] 5.6 (4.0–7.4) [11] 2.4 (1.8–2.9) [19] 7.9 (6.1–9.8) [19]
France (secondary care) 6.8 (4.6–9.4) [18] 8.2 (5.7–11.2) [7] 3.9 (2.9–5.1) [16] 13.1 (9.7–16.9) [16]
Portugal 20.4 (15.0–26.9) [19] 35.4 (22.1–45.9) [3] 23.6 (13.5–33.6) [16] 38.0 (29.4–46.9) [16]
Spain 26.6 (22.1–31.6) [53] 28.4 (23.6–33.4) [48] 16.2 (12.1–20.9) [53] 36.0 (31.0–41.2) [53]
Sweden 13.9 (12.4–15.5) [135] 16.3 (14.4–18.3) [96] 8.0 (6.7–9.4) [130] 22.5 (20.5–24.5) [130]
UK 13.9 (10.8–18.3) [110] 18.4 (13.4–26.3) [56] 10.8 (7.3–15.7) [101] 24.9 (20.9–30.1) [101]
*Bootstrap 95% CIs are given within parentheses and number of patients within square brackets.
†Time cost to patient and additional time cost to society.
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group mainly consists of those aged 65 years and
above. Where the patient group is primarily of
working age, then the cost implications will actually be
greater.
A limitation of this work is that the majority of
patients in the substudy were men; however, there is no
reason to believe that costs would differ greatly
between men and women. Additionally, data obtained
from patients, such as travel distance, may be inaccu-
rate, although there is no reason to assume that the
error would be systematic and only in one direction.
All data were self-reported and were not validated;
therefore, the responses given may be under- or over-
estimates. Nevertheless, validation was not feasible
from a practical and cost point of view, because this
would have required actual measurement of the time
associated with the monitoring visits.
The sensitivity analysis indicated a potential
problem with missing data in France and Portugal.
Nevertheless, the costs in these countries were
obtained from relatively small sample sizes and have
wide conﬁdence intervals around the mean, and there-
fore should be interpreted with caution. Additionally,
the cost results were sensitive to variation in the value
placed on leisure time.
In conclusion, patients incur considerable costs
when visiting warfarin clinics, and these costs vary by
country. The results suggest the importance of taking a
broad economic perspective when considering cost-
effectiveness of anticoagulation. This approach may
also be important where appreciable patient time and
traveling costs are likely to be incurred for either a new
technology or a baseline comparator. This is particu-
larly the case for any therapy or intervention that
requires regular monitoring.
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